Dexrazoxane

Overview

Dexrazoxane (Zinecard®) is a cytoprotective agent used in veterinary oncology primarily as an antidote to reduce the toxic effects of anthracycline chemotherapy drugs, especially doxorubicin. In dogs, it is used to minimize cardiotoxicity and to manage tissue injury caused by drug extravasation.

Clinically, dexrazoxane is most relevant in patients receiving doxorubicin that are at increased risk of cardiac damage, such as those approaching cumulative dose limits or with pre-existing cardiac disease. It is also considered an emergency treatment for doxorubicin extravasation, where early administration (within 6 hours) is critical to reduce tissue necrosis.

Mechanism of Action (MOA): Dexrazoxane is converted intracellularly to an active metabolite that chelates iron. This action prevents the formation of anthracycline–iron complexes that generate free radicals, which are responsible for cardiomyocyte damage and local tissue injury following extravasation.

Indications

Dexrazoxane is used in veterinary medicine primarily in dogs as a protective agent against the toxic effects of anthracycline chemotherapy, particularly doxorubicin. Its use is generally limited to specific clinical situations where prevention or reduction of tissue or cardiac injury is required.

• Prevention of doxorubicin-induced cardiotoxicity: Used in dogs that are at increased risk of cardiac damage, including those approaching cumulative lifetime doses of doxorubicin, showing early signs of cardiotoxicity, or with pre-existing cardiac disease.
• Treatment of doxorubicin extravasation injury: Administered as an emergency intervention to reduce local tissue damage and necrosis following accidental perivascular leakage of doxorubicin. Early administration (within 6 hours) is critical for effectiveness.
• Adjunct in anthracycline chemotherapy protocols: May be incorporated into treatment plans to allow continued use of doxorubicin in patients where cardiotoxicity is a limiting factor.

Dosage (Reference)

Dog

In dogs, dexrazoxane dosing depends on the clinical indication, particularly whether it is used for prevention of doxorubicin-induced cardiotoxicity or for treatment of extravasation injury. Timing of administration is critical, especially in extravasation cases.

Cat

There are no established or published dosing recommendations for dexrazoxane in cats. Use in this species has not been adequately studied, and safety and efficacy remain unknown.

Warnings & Precautions

Dexrazoxane is a cytoprotective agent used only in specific chemotherapy settings and should be administered with appropriate safety precautions. Careful patient selection and handling procedures are essential due to its pharmacologic effects and classification as a hazardous drug.

• Use restricted to anthracycline therapy: Dexrazoxane should only be used in patients receiving anthracycline drugs (e.g., doxorubicin). It is not indicated for use with non-anthracycline chemotherapy agents.
• Limited data in cats: Safety and efficacy in cats have not been established; use in this species is not well defined and should be approached with caution.
• Hazardous drug handling (NIOSH): Classified as a hazardous drug; appropriate personal protective equipment (PPE) must be used during preparation, administration, and disposal to minimize exposure risk.
• Myelosuppression risk: May contribute to bone marrow suppression, especially when used with other myelosuppressive chemotherapy agents; monitoring is recommended.
• Reproductive risk: May cause testicular atrophy in dogs with repeated use and has demonstrated teratogenic effects in laboratory animals; use only when benefits outweigh risks in breeding or pregnant animals.
• Handling precautions: Avoid contact of powder with skin or mucous membranes; if exposure occurs, wash thoroughly with soap and water.

Drug Interactions

Dexrazoxane has minimal direct pharmacokinetic interactions but may have clinically relevant effects when used with other drugs that influence bone marrow function. Monitoring is recommended when used concurrently with certain medications.

• Doxorubicin: Dexrazoxane does not significantly affect the pharmacokinetics of doxorubicin when administered concurrently.
• Other myelosuppressive agents: Additive myelosuppression may occur when dexrazoxane is combined with other drugs that suppress bone marrow function; careful monitoring of hematologic parameters is recommended.

Side Effects & Overdose

Side Effects

Adverse effects of dexrazoxane are primarily related to its effects on bone marrow and are most notable when used in combination with other chemotherapy agents.

• Myelosuppression: The most clinically relevant adverse effect; may be additive when used with other myelosuppressive drugs such as anthracyclines.

Overdose

Overdose of dexrazoxane is unlikely in veterinary practice due to its method of administration and cost. There is no specific antidote, and management is primarily supportive.

• No specific antidote: Treatment is supportive, including monitoring and symptomatic care.
• Supportive management: Includes fluid therapy and general clinical monitoring as needed.
• Hemodialysis: May potentially be used to enhance drug removal, although clinical experience is limited.
• Specialist consultation: Consultation with a veterinary poison control center is recommended in suspected overdose cases.

Key Notes

Practical clinical points that help optimize the safe and effective use of dexrazoxane in dogs during chemotherapy protocols:

• Time-critical use (extravasation): Effectiveness is highly dependent on early administration—ideally within 6 hours of doxorubicin extravasation.
• Pre-treatment strategy: When used for cardioprotection, dexrazoxane must be given before doxorubicin to achieve optimal protective effects.
• Allows continuation of chemotherapy: May enable continued use of doxorubicin in dogs at risk of cardiotoxicity or those approaching cumulative dose limits.
• Bone marrow monitoring: Regular CBC monitoring is important due to the risk of additive myelosuppression with chemotherapy.
• Cats limitation: Lack of safety and dosing data limits routine use in cats.
• Handling precautions: As a hazardous drug, strict handling protocols and PPE use are essential in clinical settings.